Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216274 · ClinicalTrials.gov registry record · NA
Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT07216274: Completed NA study, sponsored by Mayo Clinic.
NCT07216274 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07216274, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer. QTI is a single 3D ultrasound test intended to be used as an initial evaluation method for asymptomatic women identified with above-average risk for developing breast cancer. Using QTI may be an effective supplemental screening tool, compared to MRI for patients with a high lifetime risk of breast cancer.
Primary Outcome
Assessed by the number of positive findings. For each finding, imaging characteristics, size, and location were recorded. A Breast Imaging Reporting and Data System (BI-RADS) score was assigned for each finding. If biopsies are obtained, then findings will be compared to histopathologic diagnosis.
Interventions
- OTHER Questionnaire Administration
- DEVICE QT Ultrasound Breast Scanner
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2025-07-31 |
| Est. Completion | 2025-10-20 |
| Phase | NA |
What the finished NCT07216274 record still lists
NCT07216274 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Questionnaire Administration is the first listed.
NCT07216274 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07216274 about?
NCT07216274 is a clinical study titled "Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer". This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer. QTI is a single 3D ultrasound test intended to be used as an initial evaluation method for asymptomatic wo...
What is the current status of trial NCT07216274?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2025-07-31. Estimated completion is 2025-10-20.
What interventions are being tested in trial NCT07216274?
The interventions under investigation include: Questionnaire Administration (OTHER), QT Ultrasound Breast Scanner (DEVICE).
Who is sponsoring clinical trial NCT07216274?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07216274's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI